Evidence map›Paper›PMID 34517762›Full record

ArticlemBio2021

MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity.

Li Wang, Isabel Sola, Luis Enjuanes, Sonia Zuñiga

Open access · goldAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Li WangDepartment of Molecular and Cell Biology, National Center of Biotechnology, Universidad Autónoma de Madrid, Madrid, Spain.
Isabel SolaDepartment of Molecular and Cell Biology, National Center of Biotechnology, Universidad Autónoma de Madrid, Madrid, Spain.
Luis EnjuanesDepartment of Molecular and Cell Biology, National Center of Biotechnology, Universidad Autónoma de Madrid, Madrid, Spain.ORCID 0000-0002-0854-0226
Sonia ZuñigaDepartment of Molecular and Cell Biology, National Center of Biotechnology, Universidad Autónoma de Madrid, Madrid, Spain.
Universidad Autónoma de Madrid · ES

Funding

SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5M
European Commission (EC) IMI_JU_115760Government of Spain 202020E079Government of Spain BIO2016-75549-RGovernment of Spain PID2019-107001RB-I00HHS | National Institutes of Health (NIH) 2P01AI060699MEC | Consejo Superior de Investigaciones Científicas (CSIC) 202020E043NIAID NIH HHS P01 AI060699
6 · The paper itself

Abstract

Coronaviruses (CoVs) are emergent pathogens that may cause life-threatening respiratory diseases in humans. Understanding of CoV-host interactions may help to identify novel therapeutic targets. MOV10 is an RNA helicase involved in different steps of cellular RNA metabolism. Both MOV10 antiviral and proviral activities have been described in a limited number of viruses, but this protein has not been previously associated with CoVs. We found that during Middle East respiratory syndrome coronavirus (MERS-CoV) infection, MOV10 aggregated in cytoplasmic structures colocalizing with viral nucleocapsid (N) protein. MOV10-N interaction was confirmed by endogenous MOV10 coimmunoprecipitation, and the presence of other cellular proteins was also detected in MOV10 complexes. MOV10 silencing significantly increased both N protein accumulation and virus titer, with no changes in the accumulation of viral RNAs. Moreover, MOV10 overexpression caused a 10-fold decrease in viral titers. These data indicated that MOV10 has antiviral activity during MERS-CoV infection. We postulated that this activity could be mediated by viral RNA sequestration, and in fact, RNA immunoprecipitation data showed the presence of viral RNAs in the MOV10 cytoplasmic complexes. Expression of wild-type MOV10 or of a MOV10 mutant without helicase activity in MOV10 knockout cell lines, developed by CRISPR-Cas technology, indicated that the helicase activity of MOV10 was required for its antiviral effect. Interestingly MOV10-N interaction was conserved in other mildly or highly pathogenic human CoVs, including the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), although MOV10 antiviral activity was found only in highly pathogenic CoVs, suggesting a potential role of MOV10 in the modulation of human CoVs pathogenesis.

Indexed as

AnimalsAntiviral AgentsBlotting, WesternCell Line, TumorChlorocebus aethiopsCoronavirus Nucleocapsid ProteinsFluorescent Antibody TechniqueHumansImmunoprecipitationRNA HelicasesRNA, ViralVero CellsVirus ReplicationAntiviral AgentsCoronavirus Nucleocapsid ProteinsRNA HelicasesRNA, Viralantiviral responsecoronavirushighly pathogenic coronavirusnucleocapsid proteinvirus-host interactions

Identifiers

PMID34517762
PMCPMC8546642
OpenAlexW3199142951

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.